Literature DB >> 8444063

Pharmacokinetics of fluconazole in normal volunteers.

S Ripa1, L Ferrante, M Prenna.   

Abstract

The pharmacokinetic profile of fluconazole, after 100 mg i.v. infusion or oral administration of a single 50 mg or 150 mg dose, was investigated in 18 healthy volunteers. At a dose of 100 mg i.v., the half-life (t1/2 beta) was 29.73 +/- 8.05h. The mean residence time in the plasma was 27.56 +/- 5.98 h. The post-distributive volume V beta = 52.16 +/- 9.83 l, approximating that of total body water. Renal excretion accounted for 61.64 +/- 8.80% of the drug elimination after 48 h, with renal clearance Clr = 12.91 +/- 2.83 ml/min. Plasma clearance (Clp) was 21.03 +/- 5.07 ml/min. At oral doses of 50 and 150 mg the distribution and elimination of fluconazole resembled that following i.v. infusion. The peak levels in plasma at 2.5 h were 0.93 +/- 0.13 and 2.69 +/- 0.43 micrograms/ml, respectively. The large distribution volume, the long half-life and mean residence times, combined with a rapid absorption after oral administration, suggest that fluconazole will be effective at a wide range of body sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444063     DOI: 10.1159/000238967

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  16 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 3.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Change in blood tacrolimus concentration by fluctuation of renal function in a bone marrow transplant patient.

Authors:  Masaki Sumi; Hiroki Konishi; Yoshihiro Ikuno; Nobuo Hoshino; Tokuzo Minouchi; Akira Yamaji
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.441

5.  Fluconazole pharmacokinetics in burn patients.

Authors:  B A Boucher; S R King; H L Wandschneider; W L Hickerson; S D Hanes; V L Herring; T W Canada; M M Hess
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

Review 7.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients.

Authors:  A El-Yazigi; M Ellis; P Ernst; D Spence; R Hussain; F J Baillie
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

9.  Prediction of Tissue-Plasma Partition Coefficients Using Microsomal Partitioning: Incorporation into Physiologically based Pharmacokinetic Models and Steady-State Volume of Distribution Predictions.

Authors:  Kimberly Holt; Min Ye; Swati Nagar; Ken Korzekwa
Journal:  Drug Metab Dispos       Date:  2019-07-19       Impact factor: 3.922

Review 10.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.